![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 7
Zeitschriftenartikel
Ruethrich, Maria Madeleine; Giessen-Jung, C.; Borgmann, S.; Classen, A. Y.; Dolff, S.; Gruener, B.; Hanses, F.; Isberner, N.; Koehler, P.; Lanznaster, J.; Merle, U.; Nadalin, S.; Piepel, C.; Schneider, J.; Schons, M.; Strauss, R.; Tometten, L.; Vehreschild, J. J.; Lilienfeld-Toal, M. von; Beutel, G. und Wille, K.
(2020):
COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry.
In: Annals of Hematology, Bd. 100, Nr. 2: S. 383-393
Giessen-Jung, C.; Wollenberg, A. und Reinholz, M.
(2018):
Paraneoplasien der Haut.
In: Internist, Bd. 59, Nr. 2: S. 134-144
Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Uhlig, J.; Schenk, M.; Freiberg-Richter, J.; Peuser, B.; Denzlinger, C.; Reddemann, C. Peveling Genannt; Graeven, U.; Schuch, G.; Schwaner, I.; Stahler, A.; Jung, A.; Held, S.; Stintzing, S.; Giessen-Jung, C. und Heinemann, V.
(2017):
Sequential first-line therapy of metastatic colorectal cancer (mCRC) starting with fluoropyrimidine (FP) plus bevacizumab (BEV) vs. initial FP plus irinotecan (IRI) and BEV: German AIO KRK0110 (ML22011) study.
In: Annals of Oncology, Bd. 28
Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Uhlig, J.; Schenk, M.; Freiberg-Richter, J.; Peuser, B.; Denzlinger, C.; Reddemann, Peveling Genannt C.; Gräven, U.; Schuch, G.; Schwaner, I.; Stahler, A.; Jung, A.; Held, S.; Stintzing, S.; Giessen-Jung, C. und Heinemann, V.
(2017):
Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): german AIO KRK0110 (ML22011) - study.
In: Oncology Research and Treatment, Bd. 40: S. 123
Stocker, G.; Giessen-Jung, C.; Schmiegel, W.; Lordick, F.; Hacker, U. und Heinemann, V
(2016):
Lack of oxaliplatin dose adjustment is correlated with an increased frequency of oxaliplatin-induced neuropathy in obese patients with metastatic colorectal cancer (mCRC).
In: Oncology Research and Treatment, Bd. 39: S. 198
Stahler, A.; Heinemann, V.; Giessen-Jung, C.; Crispin, Alexander; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; Einem, J. C. von; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A. und Modest, D. P.
(2015):
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
In: International Journal of Cancer, Bd. 138, Nr. 3: S. 739-746
Heinemann, V.; Stintzing, S.; Modest, D. P.; Giessen-Jung, C.; Michl, M. und Mansmann, Ulrich
(2015):
Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC).
In: European Journal of Cancer, Bd. 51, Nr. 14: S. 1927-1936